Rigel Pharmaceuticals, Inc.: Company Profile and SWOT Analysis

Document Sample
Rigel Pharmaceuticals, Inc.: Company Profile and SWOT Analysis Powered By Docstoc
					Rigel Pharmaceuticals, Inc.

_________________________________________________________________________________



Rigel Pharmaceuticals, Inc.                                                        Financial Snapshot

                                                                                   Operating Performance
Fast Facts
                                       1180 Veterans Blvd., South San Francisco,   The company reported revenues of US$125.00 million
Headquarters Address
                                       94080,United States of America              during 2010, with a CAGR of 39.01% during 2006–
                                                                                   2010. Its revenue grew at an annual rate of
Telephone                              + 1 650 6241100
                                                                                   16566.67% over the previous fiscal year. In 2010, the
                                                                                   company recorded an operating margin of 28.25%, as
Fax                                    + 1 650 6241101                             against -14938.27% in 2009.

Website                                www.rigel.com
                                                                                   Revenue and Margins
Ticker Symbol, Stock Exchange          RIGL, NASDAQ

Number of Employees                    145

Fiscal Year End                        December

Revenue (in US$ million)               125.00




SWOT Analysis

Strengths                              Weaknesses

Focus on R&D activities                Lack of manufacturing facilities

Strategic collaborations               Overdependence on single customer

Strong top-line performance

Opportunities                          Threats

Changing demographics                  Competitive environment

Growing prevalence of cancer           Outcome of clinical trials

                                       Tightening of the FDA’s regulatory
Increasing of healthcare expenditure
                                       oversight




___________________________________________________________________________________________

Rigel Pharmaceuticals, Inc. - SWOT Profile                                                                                Page 1
Rigel Pharmaceuticals, Inc.

_________________________________________________________________________________


TABLE OF CONTENTS

1     Business Analysis ................................................................................................................................... 5
    1.1       Company Overview ................................................................................................................................................5
    1.2       Business Description ..............................................................................................................................................5
    1.3       Major Products and Services .................................................................................................................................6
2     Analysis of Key Performance Indicators ............................................................................................... 7
    2.1       Five Year Snapshot: Overview of Financial and Operational Performance Indicators ..........................................7
    2.2       Key Financial Performance Indicators .................................................................................................................10
      2.2.1       Revenue and Operating Profit .........................................................................................................................10
      2.2.2       Asset, Liabilities and Capex .............................................................................................................................11
      2.2.3       Solvency ..........................................................................................................................................................12
      2.2.4       Valuation ..........................................................................................................................................................13
    2.3       Key Competitors ...................................................................................................................................................14
3     Mergers & Acquisitions and Partnerships ........................................................................................... 15
    3.1       M&A and Partnerships Strategy ...........................................................................................................................15
4     Recent Developments ........................................................................................................................... 18
5     SWOT Analysis ...................................................................................................................................... 20
    5.1       SWOT Analysis - Overview ..................................................................................................................................20
    5.2       Strengths ..............................................................................................................................................................20
    5.3       Weaknesses .........................................................................................................................................................20
    5.4       Opportunities ........................................................................................................................................................21
    5.5       Threats .................................................................................................................................................................21
6     Rigel Pharmaceuticals, Inc. - Company Statement ............................................................................. 23
7     History .................................................................................................................................................... 25
8     Rigel Pharmaceuticals, Inc. - Key Employees ..................................................................................... 26
9     Key Employee Biographies................................................................................................................... 27
10    Appendix ................................................................................................................................................ 28
    10.1      Methodology .........................................................................................................................................................28
    10.2      Ratio Definitions ...................................................................................................................................................28
    10.3      Disclaimer.............................................................................................................................................................32




___________________________________________________________________________________________

Rigel Pharmaceuticals, Inc. - SWOT Profile                                                                                                                                  Page 2
Rigel Pharmaceuticals, Inc.

__________________________________________________________________________________________



List of Tables

Table 1: Major Products and Services ..................................................................................................................................6
Table 2: Key Ratios - Annual ..................................................................................................................................................7
Table 3: Key Ratios - Interim ..................................................................................................................................................9
Table 4: Key Capital Market Indicators ..................................................................................................................................9
Table 5: Rigel Pharmaceuticals, Inc., History .......................................................................................................................25
Table 6: Rigel Pharmaceuticals, Inc., Key Employees .........................................................................................................26
Table 7: Key Employee Biographies ....................................................................................................................................27




___________________________________________________________________________________________

Rigel Pharmaceuticals, Inc. - SWOT Profile                                                                                                                           Page 3
Rigel Pharmaceuticals, Inc.

__________________________________________________________________________________________


List of Figures

Figure 1: Revenue and Operating Profit ..................................
				
DOCUMENT INFO
Description: This SWOT analysis and company profile is a crucial resource for industry executives and anyone looking to gain a better understanding of the company's business. ICD Research's "Rigel Pharmaceuticals, Inc.: Company Profile and SWOT Analysis" report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. ICD Research strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report.
BUY THIS DOCUMENT NOW PRICE: $99 100% MONEY BACK GUARANTEED
PARTNER ICD Research
With emphasis on Insight, Consultancy and Delivery, iCD Research is a full-service, online market research agency. iCD Research is able to take advantage of all of the efficiencies and benefits that the Internet brings to offer proven research methodologies with fast turnaround and accurate results. iCD Research specialises in qualitative research for large finance, media, retail and entertainment clients. Market leaders in online focus groups, iCD Research has unleashed the full scale of the Internet to run focus groups across the globe for its major institutional clients. Utilising its sister organisation, The iD Factor, iCD Research also delivers strong quantitative research, ranging from ongoing consumer confidence studies through to consumer surveys throughout Europe and Asia. With its roots firmly in research, iCD Research doesn’t limit itself to only utilising online methods as the philosophy at the company is to match the methodology to the respondent. Yet the scale and speed of online research give iCD Research a cutting edge that has lead to tremendous, triple-figure percentage growth over the past two years. iCD Research is headquartered in London, with operational offices in the US and Australia to ensure that it is offering an unparalleled 24 hour service to its clients.